|Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)|
|Zhao, Shuiping1; Wang, Yongjun2; Mu, Yiming3; Yu, Bilian1; Ye, Ping4; Yan, Xiaowei5,6; Li, Zhanquan7; Wei, Yidong8; Ambegaonakr, Baishaili M.9; Hu, Dayi10; DYSIS-China Study Investigators|
|关键词||Cardiovascular Diseases Dyslipidaemia Statin Lipid-lowering Agents Ldl Cholesterol Non-hdl Cholesterol|
|WOS标题词||Science & Technology|
|类目[WOS]||Peripheral Vascular Disease|
|研究领域[WOS]||Cardiovascular System & Cardiology|
|关键词[WOS]||CORONARY-HEART-DISEASE ; HIGH-DENSITY LIPOPROTEIN ; CLINICAL-PRACTICE ; CHOLESTEROL GOAL ; DIABETES-MELLITUS ; HIGH-RISK ; STATIN ; MANAGEMENT ; ABNORMALITIES ; CANADA|
Background: Despite clear guideline recommendations, there is a paucity of data regarding the prevalence and type of persistent lipid profile abnormalities in patients on stable lipid-lowering therapy in China.
Methods: This cross-sectional trial included 25,697 patients treated with lipid-lowering agents from 122 centres between April 2012 and October 2012; all underwent clinical examination and had their latest fasting lipid profiles while on lipid-lowering therapy recorded. Logistic regression was performed to assess predictors for lipid abnormalities classified according to current Chinese guidelines.
Findings: Overall, 29.1% of patients had no lipid abnormalities, and 38.5% of patients did not achieve the therapeutic goal for low-density lipoprotein cholesterol (LDL-C), either as a single lipid anomaly or associated with low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides, or both. Subjects with low risk were more likely than those with very high and high risk to be at target LDL-C levels. Furthermore, 10.4% of very high-risk patients and 11.1% of high-risk patients who attained the LDL-C goal failed to attain non-HDL-C goals. Diabetes was shown to be a strong predictor of failure in attaining non-HDL-C and both goals (OR 3.03; 3.22, 95% CI 2.58-3.55; 2.73-3.79, respectively).
Conclusion: Although great improvements have been made over the past decade, the large majority of very high-risk and high-risk patients treated with lipid-lowing agents still had one or more manifestations of dyslipidaemia. Further clinical evidence is needed to clarify whether adding other lipid-lowering agents to a statin will be associated with additional cardiovascular risk reduction. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
|资助机构||Merck & ; Co., Ltd (IISP)|
|作者单位||1.Merck & Co Inc, Whitehouse Stn, NJ USA|
2.Cent S Univ, Xiangya Hosp 2, Dept Cardiol, Changsha 410011, Hunan, Peoples R China
3.Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing 100050, Peoples R China
4.Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing 100853, Peoples R China
5.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Cardiol, Beijing 100853, Peoples R China
6.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing 100730, Peoples R China
7.Peking Union Med Coll, Beijing 100730, Peoples R China
8.Peoples Hosp Liaoning Prov, Dept Cardiol, Shenyang 110016, Peoples R China
9.Tonidi Univ, Peoples Hosp 10, Dept Cardiol, Shanghai 200072, Peoples R China
10.Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100044, Peoples R China
|Zhao, Shuiping,Wang, Yongjun,Mu, Yiming,et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)[J]. ATHEROSCLEROSIS,2014,235(2):463-469.|
|APA||Zhao, Shuiping.,Wang, Yongjun.,Mu, Yiming.,Yu, Bilian.,Ye, Ping.,...&DYSIS-China Study Investigators.(2014).Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS).ATHEROSCLEROSIS,235(2),463-469.|
|MLA||Zhao, Shuiping,et al."Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)".ATHEROSCLEROSIS 235.2(2014):463-469.|